Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Total Liabilities (2016 - 2025)

Fennec Pharmaceuticals filings provide 16 years of Total Liabilities readings, the most recent being $35.1 million for Q4 2025.

  • On a quarterly basis, Total Liabilities fell 30.97% to $35.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $35.1 million, a 30.97% decrease, with the full-year FY2025 number at $35.1 million, down 30.97% from a year prior.
  • Total Liabilities hit $35.1 million in Q4 2025 for Fennec Pharmaceuticals, down from $53.8 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $66.2 million in Q1 2024 to a low of $2.9 million in Q1 2021.
  • Median Total Liabilities over the past 5 years was $29.5 million (2022), compared with a mean of $32.9 million.
  • Biggest five-year swings in Total Liabilities: soared 344.26% in 2022 and later tumbled 30.97% in 2025.
  • Fennec Pharmaceuticals' Total Liabilities stood at $6.6 million in 2021, then skyrocketed by 344.26% to $29.5 million in 2022, then skyrocketed by 30.43% to $38.5 million in 2023, then soared by 32.04% to $50.8 million in 2024, then tumbled by 30.97% to $35.1 million in 2025.
  • The last three reported values for Total Liabilities were $35.1 million (Q4 2025), $53.8 million (Q3 2025), and $52.3 million (Q2 2025) per Business Quant data.